��������

Ramy A. Mahmoud is the current CEO & Director at Optinose. Ramy has also previously held the position of Board Member and Vice President, Medical Affairs at Janssen, Pharmaceutical Companies of Johnson and Johnson from January 1999 to December 2007. In November 2021, they started Optinose Inc., a specialty healthcare company with an ENT/Allergy focus. In 2010, they acquired a company (OptiNose AS) with patents on a novel nasal delivery technology and led a world-class team that used the technology to successfully develop 2 products from pre-NDA through FDA approval. The first product, Onzetra, was successfully out-licensed. The second, Xhance, was launched by Optinose following one of the most successful biopharma IPOs of 2017. Research is ongoing for world-first chronic sinusitis indication and for an anti-COVID treatment. Mr. Mahmoud has also been named EY entrepreneur of the year and earned Philadelphia "Best Places to Work" multiple years running.

and Michael C. Berkey - VP, Technical Operations reports to Ramy A. Mahmoud. They work with Anthony Krick - Chief Accounting Officer, Victor Clavelli - Chief Commercial Officer, and John Messina - SVP, Clinical Development & Medical Affairs. Ramy A. Mahmoud reports to Peter K. Miller, CEO & Director.